MYCN and neuroblastoma: Importantly, we have proved that targeting KLHL37 leads to remarkable suppression of MYCN-amplified neuroblastoma in vitro and in vivo, indicting that KLHL37 is an appropriate therapeutic target for neuroblastoma.